A new method of producing NS5A antigen of hepatitis C virus
- Authors: Kuznetsova T.V.1,2, Smirnova M.S.1, Leonovich O.A.1, Gordeichuk I.V.1, Biriukova I.K.1, Zylkova M.V.1, Tyn’O Y.Y.1, Belyakova A.V.1, Shevelev A.B.1
-
Affiliations:
- Chumakov institute of Poliomyelitis and Viral Encephalitides
- National institute of Public Health Development
- Issue: Vol 62, No 1 (2017)
- Pages: 17-25
- Section: ORIGINAL RESEARCHES
- URL: https://medbiosci.ru/0507-4088/article/view/117902
- DOI: https://doi.org/10.18821/0507-4088-2017-62-1-17-25
- ID: 117902
Cite item
Full Text
Abstract
About the authors
T. V. Kuznetsova
Chumakov institute of Poliomyelitis and Viral Encephalitides; National institute of Public Health Development
Author for correspondence.
Russian Federation
M. S. Smirnova
Chumakov institute of Poliomyelitis and Viral EncephalitidesRussian Federation
O. A. Leonovich
Chumakov institute of Poliomyelitis and Viral EncephalitidesRussian Federation
I. V. Gordeichuk
Chumakov institute of Poliomyelitis and Viral EncephalitidesRussian Federation
I. K. Biriukova
Chumakov institute of Poliomyelitis and Viral Encephalitides
Email: kudykina_yuliya@mail.ru
Russian Federation
M. V. Zylkova
Chumakov institute of Poliomyelitis and Viral EncephalitidesRussian Federation
Ya. Ya. Tyn’O
Chumakov institute of Poliomyelitis and Viral EncephalitidesRussian Federation
A. V. Belyakova
Chumakov institute of Poliomyelitis and Viral EncephalitidesRussian Federation
A. B. Shevelev
Chumakov institute of Poliomyelitis and Viral EncephalitidesRussian Federation
References
- Benkovic S.J., Putney S.D., Schimmel P.R. Method for Degrading DNA. Patent USA № 4521509; 1985.
- Sugino Y., Morita M., Matuo Y., Uchida K. Method for Producing DNA Nested Deletions by an in Vitro Reaction Using Transposase. Patent USA № 6265159; 2001.
- Whitcomb J.M., Rashtchian A., Hughes S.H. A new PCR based method for the generation of nested deletions. Nucleic Acids Res. 1993; 21(17): 4143-6.
- Bouzgarrou N., Hassen E., Mahfoudh W., Gabbouj S., Schvoerer E., Ben Yahia A. et al. NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy. J. Med. Virol. 2009; 81(12): 2021-8.
- MacDonald A., Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. J. Gen. Virol. 2004; 85(9): 2485-502.
- Muñoz de Rueda P., Casado J., Patón R., Quintero D., Palacios A., Gila A. et al. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses. J. Virol. 2008; 82(13): 6644-53.
- Noguchi T., Tamori A., Ogura N., Hori Y., Ikeda S., Nishiguchi S. Investigation of interferon-α response by a single amino acid substitution of nonstructural protein 5A in hepatitis C virus-infected patients. J. Interferon Cytokine Res. 2011; 31(8): 589-99.
- Sillanpää M., Melén K., Porkka P., Fagerlund R., Nevalainen K., Lappalainen M. et al. Hepatitis C virus core, NS3, NS4B and NS5A are the major immunogenic proteins in humoral immunity in chronic HCV infection. J.Virol. 2009; 6: 84.
- Desombere I., Van Vlierberghe H., Weiland O., Hultgren C., Sällberg M., Quiroga J. et al. Serum levels of anti-NS4a and anti-NS5a predict treatment response of patients with chronic hepatitis C. J. Med Virol. 2007; 79(6): 701-13.
- Swadling L., Capone S., Antrobus R.D., Brown A., Richardson R., Newell E.W. et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci. Transl. Med. 2014; 6(261): 261ra153.
Supplementary files

